Qlucore, listed on Nasdaq First North, can now present the first results from an EU-funded project for improved diagnosis of lung cancer. The new classification model not only separates different. | May 30, 2023
The company expects that this work to develop and validate classifier models for bladder cancer will lead to a CE mark for its Qlucore Diagnostics software platform.
Qlucore receives second commercial order for new solutionThe Swedish Nasdaq First North listed software company Qlucore, focused on cancer diagnostics, has signed an agreement with the Molecular Oncohematology Research Group at the Department of Pathology and Experimental Cancer Research at Semmelweis University. Th.